Macitentan cuts morbidity, death in pulmonary arterial HTN

Macitentan cuts morbidity, death in pulmonary arterial HTN
For patients with pulmonary arterial hypertension, the new dual endothelin-receptor antagonist macitentan is associated with reductions in morbidity and mortality, according to a study published in the Aug. 29 issue of the New England Journal of Medicine.

(HealthDay)—For patients with pulmonary arterial hypertension, the new dual endothelin-receptor antagonist macitentan is associated with reductions in morbidity and mortality, according to a study published in the Aug. 29 issue of the New England Journal of Medicine.

Tomás Pulido, M.D., from the Ignacio Chávez National Heart Institute in Mexico City, and colleagues assessed the efficacy of macitentan for patients with symptomatic pulmonary arterial hypertension. Participants were randomized to receive placebo (250 patients), 3-mg macitentan once-daily (250 patients), and 10-mg macitentan once daily (242 patients). The primary end point was the time from treatment initiation to first occurrence of a composite of death, atrial septostomy, , initiation of treatment with intravenous or subcutaneous prostanoids, or pulmonary arterial hypertension worsening.

The researchers found that the primary end point occurred in 46.4, 38.0, and 31.4 percent of patients in the placebo, 3-mg, and 10-mg groups, respectively. Compared with placebo, the hazard ratios for the 3-mg and 10-mg macitentan doses were 0.70 and 055, respectively. The most frequent primary end point event was worsening of pulmonary arterial hypertension. The impact of macitentan on this end point was seen regardless of baseline pulmonary arterial hypertension therapy. Headache, nasopharyngitis, and anemia were the most frequent associated with macitentan.

"In conclusion, macitentan significantly reduced morbidity and mortality among patients with ," the authors write.

The study was funded by Actelion Pharmaceuticals, the manufacturer of macitentan.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Tofacitinib ups rheumatoid arthritis treatment response

Aug 22, 2013

(HealthDay)—The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs), according to a study published ...

Recommended for you

Location of body fat can increase hypertension risk

14 minutes ago

People with fat around their abdominal area are at greater risk of developing hypertension when compared to those with similar body mass index but fat concentrations elsewhere on the body, according to a ...

Fruit consumption cuts CVD risk by up to 40 percent

4 hours ago

Daily fruit consumption cuts the risk of cardiovascular disease (CVD) by up to 40%, according to research presented at ESC Congress today by Dr Huaidong Du from Oxford, UK. The findings from the seven year ...

User comments